Autophagy activation in breast cancer cells in vitro after the treatment with PI3K/AKT/mTOR inhibitors

D. D. Grigoreva,E. M. Zhidkova,E. S. Lylova,A. D. Enikeev,K. I. Kirsanov,G. A. Belitsky,M. G. Yakubovskaya,E. A. Lesovaya
DOI: https://doi.org/10.17650/2313-805x-2022-9-4-61-70
2022-12-17
Advances in molecular oncology
Abstract:Introduction . Current chemotherapy of breast cancer has a wide range of disadvantages, in particular, the development of therapy-related infections and hormonal imbalance. Combination of main cytostatic with glucocorticoids allows to broaden its therapeutic interval and to decrease the total toxicity of the treatment. However, long-term treatment with glucocorticoids leads to the development of severe side effects via activation of multiple molecular mechanisms. Thus, glucocorticoids activate prosurvival mTOR-dependent autophagy. Therefore, the evaluation of PI3K (phosphoinositide 3-kinases) / Akt (protein kinase B) / mTOR (mammalian target of rapamycin) inhibitors as adjuvants for breast cancer therapy is important for optimization of treatment protocol. Aim . Analysis of the effects of PI3K/Akt/mTOR inhibitors, rapamycin, wortmannin and LY-294002 in combination with glucocorticoids in breast cancer cell lines of different subtypes. Materials and methods . We demonstrated the inhibition of PI3K/Akt/mTOR signaling and the autophagy induction after the treatment of breast cancer cells with rapamycin, wortmannin and LY-294002 by Western blotting analysis of Beclin-1, phospho-Beclin-1 (Ser93 and Ser30). Conclusion . PI3K/Akt/mTOR inhibitors in combination with Dexamethasone cooperatively inhibited mTOR signaling and activated autophagy in breast cancer cells in vitro.
What problem does this paper attempt to address?